Oncolytics Biotech Inc. (NASDAQ: ONCY) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Oncolytics Biotech Inc. (NASDAQ: ONCY) was downgraded by analysts at Leede Financial from a "strong-buy" rating to a "moderate buy" rating.
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon